Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name AB154 + Zimberelimab
Synonyms
Therapy Description

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
AB154 AB-154|AB 154|Domvanalimab Immune Checkpoint Inhibitor 147 TIGIT Antibody 19 AB154 (domvanalimab) is a monoclonal antibody that targets T-cell immunoreceptor with Ig and ITIM domains (TIGIT), potentially resulting in enhanced immune response (Cancer Immunol Res 2019;7(2 Suppl):Abstract nr A124).
Zimberelimab GLS-010|AB122|AB-122|GLS010 Immune Checkpoint Inhibitor 147 PD-L1/PD-1 antibody 117 Zimberelimab (GLS-010) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (PMID: 28679395).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT04262856 Phase II AB154 + Etrumadenant + Zimberelimab Zimberelimab AB154 + Zimberelimab Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer (ARC-7) Active, not recruiting USA | CAN | AUS 4
NCT05130177 Phase II AB154 + Zimberelimab Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma Recruiting USA 0
NCT03628677 Phase I AB154 AB154 + Zimberelimab A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies Active, not recruiting USA | AUS 0
NCT04736173 Phase III Zimberelimab Carboplatin + Paclitaxel + Pemetrexed Disodium AB154 + Zimberelimab Pembrolizumab Study Comparing the Combination Domvanalimab and Zimberelimab With Pembrolizumab in Untreated Locally Advanced or Metastatic PD-L1-High Non-Small Cell Lung Cancer (ARC-10) Active, not recruiting USA | FRA 16
NCT04656535 Phase I Zimberelimab AB154 AB154 + Zimberelimab AB154 Combined With AB122 for Recurrent Glioblastoma Recruiting USA 0
NCT05676931 Phase II AB680 + Zimberelimab AB154 + Zimberelimab AB154 + AB680 + Zimberelimab AB680 + Docetaxel + Zimberelimab AB154 + Docetaxel + Zimberelimab Study With Immunotherapy Combinations in Participants With Metastatic Non-Small Cell Lung Cancer (EDGE-Lung) Recruiting USA | GBR | ESP | AUS 2
NCT05724563 Phase II AB154 + Zimberelimab Domvanalimab and Zimberelimab in Advanced Liver Cancers Recruiting USA 0
NCT05329766 Phase II AB680 + Zimberelimab AB154 + Fluorouracil + Leucovorin + Oxaliplatin + Zimberelimab AB154 + Zimberelimab Fluorouracil + Leucovorin + Oxaliplatin + Zimberelimab A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies (EDGE-Gastric) Recruiting USA | FRA | CAN 2


Additional content available in CKB BOOST